The GAINS trial - Growth and Anabolism In Intensive care Survivors

Matthew Anstey (matthew.anstey@health.wa.gov.au)
Sir Charles Gairdner Hospital
https://orcid.org/0000-0001-7927-524X

Rashmi Rauniyar
Sir Charles Gairdner Hospital

Ethan Fitz Clarence
Sir Charles Gairdner Hospital

Ngan Tran
Sir Charles Gairdner Hospital

Emma Osnain
Sir Charles Gairdner Hospital

Bianca Mammana
Sir Charles Gairdner Hospital

Angela Jacques
University of Notre Dame

Robert N Palmer
Sir Charles Gairdner Hospital

Andrew Chapman
Royal Perth Hospital

Bradley Wibrow
Sir Charles Gairdner Hospital

Research

Keywords: intensive care, Androgens, Nandrolone, Critical Illness, Quality of Life, Muscle Strength

DOI: https://doi.org/10.21203/rs.3.rs-133539/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background

To explore the feasibility, safety and potential benefits from administration of nandrolone to patients in the recovery phase from critical illness weakness.

Methods

In this phase 2 randomized controlled trial, adult critically ill patients admitted for longer than 7 days with significant weakness, received nandrolone ((males 200 mg, females 100 mg) or placebo weekly, up to a total of three doses. Primary outcome measures were improvement in grip strength, medical research council (MRC) muscle strength sum score, and functional activity level (Chelsea critical care assessment tool (CPAx)).

Results

22 patients were enrolled between September 2017 and May 2019. No significant adverse events were detected. Median grip strength change was non-significantly greater in the nandrolone group (left hand (9.9 vs 4.4, p = 0.190), right (5.8 vs 3.0, p = 0.343)). The discharge CPAx and ICU mobility scores scores were higher in the nandrolone group, although there was no difference in the change in CPAx score (16.4 vs 17.2, p = 0.865). There were no changes in ultrasound detected muscle thickness between groups.

Conclusions

In patients with prolonged critical illness, nandrolone appears to be safe but a larger study, potentially combined with resistance exercise, is needed to definitively address the potential benefits.

Trial registration: ANZCTR registration number : ACTRN12616000835448. Registered 27/6/2016.

https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=370920

Introduction

Intensive Care Unit (ICU) acquired weakness, the result of catabolism, immobility and critical illness polymyoneuropathy, is of significant consequence to long-stay ICU patients. [1] Despite recent advances in prevention through rehabilitation and nutrition, it is estimated that one-quarter to one-half of long-stay ICU survivors live with significant weakness as a consequence of their illness, resulting in impaired mobility and function.[2, 3] The loss of lean body mass in critical illness is related to prolonged catabolism, immobility and critical illness polymyoneuropathy, but is also associated with misalignment between catabolic and anabolic hormones.[4–6] Testosterone levels in critically ill patients are extremely low, even in the recovery phase from acute illness. [7, 8]One potential treatment may be to provide anabolic support in the recovery phase from prolonged critical illness. [9]
Anabolic steroids stimulate protein and muscle synthesis. Many synthetic anabolic steroids have had modifications to the testosterone structure to maximise anabolic properties, whilst attempting to eliminate the androgenic effects. Nandrolone or oxandrolone exhibit significantly greater selectivity for myotropic properties, with minimal androgenic effects.[10] potentially minimising any adverse outcomes.

Nandrolone has previously been used successfully (compared with testosterone or placebo) in a randomized controlled trial to reverse weight loss in human immunodeficiency virus/acquired immunodeficiency sydnrome (HIV/AIDS) patients.[7–9] It has also been used in patients with chronic obstructive pulmonary disease (COPD) to improve respiratory function and muscle wasting.[10] Testosterone and oxandrolone have been shown to have beneficial effects on muscle catabolism in patients with burns.[11] Small previous studies have suggested nandrolone to be beneficial for patients recovering from critical illness.[12, 13]

We designed a phase II randomised controlled trial to explore the feasibility, safety and potential benefits on muscle strength and recovery from critical illness from nandrolone, or placebo. The primary objective of this trial was to assess whether nandrolone can improve muscle strength and functional recovery in deconditioned ICU patients.

**Methods**

**Trial design**

This investigator initiated study was a placebo controlled, randomised clinical trial conducted in two adult tertiary level ICUs in Perth Western Australia between September 2017 and May 2019. The study was approved by the Sir Charles Gairdner and Osborne Park Hospital HREC: RGS0000001841. Prospective registration of the trial was made on Australian and New Zealand Clinical Trials Registry (ACTRN12616000835448) and a clinical trials notification to the Therapeutic Goods Administration of the Australian Department of Health was made (CT-2016-CTN-02891).

**Patients**

Adult patients were eligible to participate if they had been admitted to the ICU for more than seven days, and had significant weakness as deemed by the treating clinician or weight loss (weight loss defined as body mass index (BMI) < 20 or greater than 10% weight loss in the last 6 months) as a result of the ICU stay or pre-ICU condition. Patients needed to be able to interact with physiotherapy, and to be receiving nutrition at estimated goal rate for at least 3 days prior to enrolment. Key exclusion criteria included inability to consent, intercurrent septic shock (defined as infection requiring vasopressor support), prostate or breast cancer, active cardiac disease (myocardial infarction in last two weeks or ejection fraction < 35%), ongoing non-curable reason for catabolic state (such as active malignancy, HIV with opportunistic infection or inadequate nutritional intake), normal baseline level of serum testosterone, pregnancy, nephrotic syndrome (proteinuria > 3 g/day) or elevated liver function tests (alanine aminotransferase > 5x normal) and impaired bilirubin excretion.
Randomisation and Blinding

Participants were randomised in a 1:1 ratio to receive nandrolone or placebo using a computer-generated randomisation list. The randomisation list was generated by an independent statistician, stratified by site and provided directly to the pharmacist responsible for preparing the study drug. The clinical teams, research staff and patients were masked to treatment allocation. To ensure blinding at administration, both the placebo (sterile water) and study drug were prepared in masked syringes (covered in aluminium foil) so that the contents were not visible to the person administering them.

Study Treatment

Intramuscular doses of nandrolone or placebo were administered into the lateral thigh, delivered weekly, up to a total of 3 doses. Female participants received 100 mg and males 200 mg. The dose selection was based on our own previous experience, as well as published data from other patient populations, and duration based on the likelihood of the patients still remaining in hospital for ongoing administration and measurements.[11–13] The first dose was administered while the patient was still in the ICU, but subsequent doses could be given when the patient had gone to the ward. The study drug was only administered if the patient was still in hospital, and thus not all patients received 3 doses.

Standard clinical management

No other changes to standard clinical management of these patients occurred. Improvements in critical illness weakness may also result from changes in physical therapy or nutrition. Estimates of daily caloric and protein intake were recorded by dietitians using food intake records, as well as duration of physical therapy received. The ICUs involved have dedicated physiotherapists and early rehabilitation is encouraged.

Outcome Measures

The primary outcome measures were an improvement in strength measures. The measures chosen were grip strength, measured by hand dynamometry, medical research council (MRC) muscle strength sum score, and functional activity level using the Chelsea critical care assessment tool (CPAx).[14] Hand dynamometry, MRC and CPAx scores were all measured by trained physiotherapists. Secondary outcome measures were change in body weight, mid arm circumference, ultrasound measured quadriceps muscle thickness, ICU length of stay (LOS) and hospital LOS. Ultrasound measurements were taken by two trained clinicians, using previously described protocols.[15] All measures were taken at baseline and then weekly until discharge. MRC and CPAx were measured up to hospital discharge whereas the ICU mobility scale was measured until ICU discharge. Blood tests were also taken to monitor testosterone levels, haemoglobin, cholesterol and liver function. A follow-up phone call at 3 months following discharge was planned to assess the patient's functional state using the SF-36 score.

Statistical Analysis
As a phase II pilot study, an a priori sample size calculation to detect a specific effect size difference was not undertaken. Descriptive statistics were based on frequency distributions for categorical data and means, standard deviations, medians, IQRs, and ranges for continuous data. Group comparisons were based on treatment groups. Univariate analysis include $\chi^2$ and Fisher Exact tests, as appropriate, for categorical comparisons, and Mann-Whitney $U$ tests and $t$ tests for comparison of continuous outcomes. Ventilation and LOS durations were estimated using Kaplan-Meier survival probabilities, with Log-Rank tests used to test group differences. Linear mixed models incorporating random subject effects were used to examine group differences in nutritional, physical rehabilitation and hormonal measures at days 1, 7, 14 and 21. Results are summarised as predicted marginal means and corresponding 95% CI. Outcome variables were dichotomised according to accepted cutoffs (MRC score < 48 = ICU acquired weakness, CPAx score $\leq$ 18 (at risk of physical disability on discharge[16] and ICU mobility scale score of 8 (walking with one assist). Statistical analysis was conducted using Stata 16.0 (StataCorp LLC, College Station, Texas) and IBM SPSS version 26.0 (Armonk, NY). All hypothesis tests are 2-sided, and $P$ values $< 0.05$ are considered statistically significant.

**Results**

A total of 22 patients were enrolled in the study (21 at Sir Charles Gairdner and 1 at Royal Perth Hospital), with 11 in each group (Figure 1). Patients had a mean (SD) age of 66 (11) years, were predominantly male (13/22) and had an initial mean APACHE III score of 39.5 (26.6). Baseline characteristics are outlined in Table 1. Patients received their first dose of nandrolone, on average at day 15 after ICU admission. Despite randomisation, there were some differences in the baseline mobility and strength characteristics between the two groups. While these may have occurred due to chance, Medical research sum score (40.5 vs 28.2, $p= 0.001$), Critical Care Physical Assessment tool score (24.7 vs 14.8, $p=0.011$), ICU mobility scale (5.1 vs 2.9, $p=0.005$) and grip strength (9.6 vs 3.4 on the right, $p = 0.165$)) were all higher in the nandrolone groups at baseline (Table 1 and supplementary table 1). A CPAx score $\leq$ 18 (at risk) has previously categorised patients at risk of physical disability on discharge, and in this cohort, there was no significant difference between the groups ($p=0.67$).[16] Table 2 outlines the treatments received in the rehabilitation period, with the placebo group receiving more calories, protein and physiotherapy input.

**Primary outcome**

Table 3 shows the improvement in strength in the two groups. MRC change (from baseline to end measurement) was significantly higher in the placebo group (17.6 vs 9.3, $p=0.001$). Median grip strength change was non-significantly greater in the nandrolone group, for the left hand (9.9 vs 4.4, $p =0.190$), and the right (5.8 vs 3.0, $p = 0.343$). The discharge CPAx score and the discharge ICU mobility scores were higher in the nandrolone group, although there was no significant difference in the change in CPAx score (16.4 vs 17.2, $p=0.865$).

**Secondary outcomes**
More patients were discharged home in the nandrolone group than the placebo group (6 vs 0). Length of ICU (23 vs 14 days) and hospital (36 vs 26 days) stay, and mechanical ventilation (377 vs 168 hours) were all shorter in the nandrolone group, but with no difference in hospital or 90 day survival in either group. Supplemental table 1 outlines the changes in ultrasound measured quadriceps thickness over time, weight and biceps diameter, with no significant changes over time in these measurements between groups.

SF-36 results were available for 16 patients at 3 months after enrolment. Table 4 outlines the results by domain. All but 3 patients (in the nandrolone group) were living independently prior to hospitalisation. There was a non-significant trend towards improved physical functioning (56.6 vs 40.7, p=0.32) and reduced limitations due to physical functioning (58.3 vs 17.9, p =0.076) and reduction in pain (77.6 vs 47.4, p=0.065) in the nandrolone group, but no changes in the other domains.

Safety

We did not detect any adverse effects from nandrolone on the blood parameters we monitored (renal, liver function and lipids) (supplemental table 1). We did not record any other pre-specified significant adverse events with regards to cardiac failure or virilisation.

Study drug administration

Table 2 outlines the number of doses of study drug received in the two groups. 7 of the patients in the nandrolone group received 2, whereas 7 of the placebo group received 3 doses. All patients received at least one dose.

Discussion

To our knowledge, this is the first non-burns ICU randomized controlled study to look at the use of anabolic steroids. It showed that the administration of nandrolone to ICU patients with ICU acquired weakness appears to be both safe and feasible. There were no consistent significant differences in the primary outcomes between the two groups. Although the MRC change was greater in the placebo groups, the other co-primary outcomes showed no difference.

The cohort of patients studied appears to be representative of those with ICU acquired weakness. They had significant weakness, with baseline grip strength readings consistent with accepted cut-offs for ICU acquired weakness and MRC scores well below 48.[17] In keeping with the biological plausibility of providing anabolic steroids, these patients were testosterone deficient. [8]

In the nandrolone group, more patients were discharged home from hospital, with higher discharge CPAX and MRC scores. SF-36 scores in pain and limitations due to physical functioning at 3 months were also higher in the nandrolone group. However, as secondary outcomes these findings can only be hypothesis generating and are not reflected by the other outcome measures. The increase in MRC (change) was actually greater in the placebo group and while grip strength change was greater in the nandrolone group,
it was not significant, and there was no significant improvement in MRC scores, mobility scores or ultrasound measurements in the patients who received nandrolone. This may reflect the fact that we did not incorporate resistance exercise into the rehabilitation program, potentially a required component of muscle hypertrophy.[18]

We had considered the use of ultrasound might have been able to detect more subtle changes in muscle size.[15, 19] The lack of change seen may be because the duration of observation was not long enough to detect changes in muscle size, or nandrolone did not accelerate muscle growth compared with placebo, or that changing fluid status in recovering patients affected the readings. Muscle wasting in the ICU occurs early (in the first 1–2 weeks), and a recent study showed no correlation between caloric or protein debt and muscle thickness over one week. [20]

In setting up the trial, we wanted to measure the traditional components of ICU recovery – nutrition and physical rehabilitation. Early rehabilitation and dietitian review is standard practice in the participating ICUs. Of note, the placebo group received more calories and protein replacement, as well as more physiotherapy time, making it harder to separate out the contribution of nandrolone alone to the patients’ recovery. We hypothesise that since the placebo group had longer duration of mechanical ventilation, they also more likely had a longer duration of nasogastric enteral feeding, which makes it easier to achieve nutritional targets (especially in the recently extubated patients), and longer duration of physiotherapy as they were receiving ventilator weaning assistance.

There are several limitations that need to be addressed. First, despite randomisation, there appears to be a degree of mismatch in the underlying characteristics of the enrolled patients. At baseline, the placebo group (which ended up having longer duration of mechanical ventilation) had lower MRC, CPAx and ICU mobility scale scores. The differences in length of stay are likely to reflect these baseline differences rather than the nandrolone. Understanding why the randomisation process wasn’t entirely successful might relate to the heterogeneity of patients with ICU acquired weakness and the sample size. Second, whilst two ICUs were involved, the patients were predominantly enrolled from one ICU. Third, as a pilot study, the study was not powered to detect differences between the groups but rather to test the feasibility of the protocol and establish pilot data to guide further studies. Finally, this study did not address whether the dosing schedule and dose chosen were optimal. We elected to provide up to 3 doses based on estimates of how long patients would remain in hospital. It may be that a more prolonged course of nandrolone would be more beneficial, as used by authors in different settings, and combined with resistance exercise to promote muscle growth.[12, 21] Indeed, a single dose of nandrolone has not been shown to attenuate muscle atrophy during disuse.[22] However, a longer duration trial would require coordination across departments and settings.

**Conclusion**

Addressing persistent catabolism and testosterone deficiency has been suggested as a potential treatment for ICU acquired weakness. [23] In patients with prolonged critical illness, nandrolone appears
to be safe but a larger study, potentially also with a longer duration of nandrolone administration, is needed to definitively address the potential benefits.

**Declarations**

Ethics approval and consent to participate: The study was approved by the Sir Charles Gairdner and Osborne Park Hospital HREC: RGS0000001841. All patients provided written consent to participate.

Consent for publication N/A

Availability of data and material: The datasets generated during and/or analysed during the current study are not publicly available due to ethics approval restrictions but are available from the corresponding author on reasonable request.

Competing interests: The authors have no competing interests to declare.

Funding: There was no funding available for this study.

Authors’ contributions: MA: Conceptualization, Investigation, Methodology, Writing-original, Supervision BW: Conceptualization, Investigation, Methodology, Writing- Reviewing and Editing. EM : Data curation, Investigation. Writing- Reviewing and Editing, NT,BM,EO, AC: Investigation, Methodology, Writing- Reviewing and Editing. EF: Data curation, Investigation. Writing- Reviewing and Editing, AJ: Analysis, Methodology, Writing - Reviewing and Editing.

Acknowledgements: Ms Sharon Waterson, Erina Myers, Amanda Ziatas and Dr Amanda Wilson for assistance with data collection.

**References**

1. Kress JP, Hall JB. ICU-Acquired Weakness and Recovery from Critical Illness. New England Journal of Medicine. 2014;370:1626–35.
2. Dinglas VD, Friedman LA, Colantuoni E, Mendez-Tellez PA, Shan Holtz CB, Ciesla ND, et al. Muscle Weakness and 5-Year Survival in Acute Respiratory Distress Syndrome Survivors. Crit Care Med. 2017;45:446–53.
3. Herridge MS, Tansey CM, Matté A, Tomlinson G, Diaz-Granados N, Cooper A, et al. Functional disability 5 years after acute respiratory distress syndrome. New England Journal of Medicine. 2011;364:1293–304.
4. Gamrin L, Andersson K, Hultman E, Nilsson E, Essén P, Wernerman J. Longitudinal changes of biochemical parameters in muscle during critical illness. Metabolism - Clinical and Experimental. Elsevier; 1997;46:756–62.
5. Puthucheary ZA, Rawal J, McPhail M, Connolly B, Ratnayake G, Chan P, et al. Acute skeletal muscle wasting in critical illness. Jama. American Medical Association; 2013;310:1591–600.
6. Preiser J-C, Ichai C, Orban J-C, Groeneveld ABJ. Metabolic response to the stress of critical illness. British journal of anaesthesia. Oxford University Press; 2014;113:945–54.

7. Nierman DM, Mechanick JI. Hypotestosteronemia in chronically critically ill men. Crit Care Med. 1999;27:2418–21.

8. Almoosa KF, Gupta A, Pedroza C, Watts NB. Low Testosterone Levels are Frequent in Patients with Acute Respiratory Failure and are Associated with Poor Outcomes. Endocr Pract. 2014;20:1057–63.

9. Vincent J-L. Metabolic support in sepsis and multiple organ failure: More questions than answers …. Critical Care Medicine. 2007;35:S436–40.

10. Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008;154:502–21.

11. Anstey M, Desai S, Torre L, Wibrow B, Seet J, Osnain E. Anabolic Steroid Use for Weight and Strength Gain in Critically Ill Patients: A Case Series and Review of the Literature [Internet]. Case Reports in Critical Care. Hindawi; 2018 [cited 2020 Sep 9]. p. e4545623. Available from: https://www.hindawi.com/journals/cricc/2018/4545623/

12. Gold J, Batterham MJ, Rekers H, Harms MK, Geurts TBP, Helmyr PME, et al. Effects of nandrolone decanoate compared with placebo or testosterone on HIV-associated wasting. HIV Med. 2006;7:146–55.

13. Pikul J, Sharpe MD. Use of anabolic steroid therapy in critically ill ICU patients. Critical Care. 2003;7:P014.

14. Corner EJ, Wood H, Englebretsen C, Thomas A, Grant RL, Nikoletou D, et al. The Chelsea critical care physical assessment tool (CPAx): validation of an innovative new tool to measure physical morbidity in the general adult critical care population; an observational proof-of-concept pilot study. Physiotherapy. 2013;99:33–41.

15. Tillquist M, Kutsogiannnis DJ, Wischmeyer P, Kummerlen C, Leung R, Stollery D, et al. Bedside Ultrasound Is a Practical and Reliable Measurement Tool for Assessing Quadriceps Muscle Layer Thickness. J Parenter Enter Nutr. 2013;

16. Milton A, Schandl A, Soliman I, Joelsson-Alm E, Boogaard M van den, Wallin E, et al. ICU discharge screening for prediction of new-onset physical disability—A multinational cohort study. Acta Anaesthesiologica Scandinavica. 2020;64:789–97.

17. Ali NA, O’Brien JM, Hoffmann SP, Phillips G, Garland A, Finley JCW, et al. Acquired weakness, handgrip strength, and mortality in critically ill patients. Am J Respir Crit Care Med. 2008;178:261–8.

18. Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, et al. The Effects of Supraphysiologic Doses of Testosterone on Muscle Size and Strength in Normal Men. New England Journal of Medicine. Massachusetts Medical Society; 1996;335:1–7.

19. Segers J, Hermans G, Charususin N, Fivez T, Vanhorebeek I, Van den Berghe G, et al. Assessment of quadriceps muscle mass with ultrasound in critically ill patients: intra- and inter-observer agreement and sensitivity. Intensive Care Med. 2015;41:562–3.

20. Pardo E, El Behi H, Boizeau P, Verdonk F, Alberti C, Lescot T. Reliability of ultrasound measurements of quadriceps muscle thickness in critically ill patients. BMC Anesthesiol. 2018;18:205.
21. Johansen KL, Mulligan K, Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA. 1999;281:1275–81.

22. Horstman AMH, Backx EMP, Smeets JSJ, Marzuca-Nassr GN, Kranenburg J van, Boer D de, et al. Nandrolone decanoate administration does not attenuate muscle atrophy during a short period of disuse. PLOS ONE. 2019;14:e0210823.

23. Wischmeyer PE, Suman OE, Kozar R, Wolf SE, Molinger J, Pastva AM. Role of anabolic testosterone agents and structured exercise to promote recovery in ICU survivors. Current Opinion in Critical Care. 2020;26:508–515.

Tables

Table 1. Baseline Characteristics of Study Participants by Treatment Group
| Characteristics                                      | Placebo (n = 11) | Nandrolone (n = 11) |
|-----------------------------------------------------|-----------------|---------------------|
| **Demographics**                                    |                 |                     |
| Sex, n (%)                                          |                 |                     |
| Female                                              | 5 (45.5%)       | 4 (36.4%)           |
| Age, years                                          | 62.7 (11.9)     | 69.7 (9.6)          |
| Body mass index (BMI), kg/m²                         | 26.9 (5.9)      | 26.9 (7.4)          |
| Body mass index (BMI), <18.5 kg/m²                  | 1 (9.1)         | 2 (18.2)            |
| Body mass index (BMI), >30 kg/m²                    | 4 (36.4)        | 4 (36.4)            |
| Residence prior to admission                        |                 |                     |
| Own home                                            | 11 (100%)       | 8 (72.7)            |
| Supports at home                                    | 0               | 3 (27.3)            |
| APACHE III score                                    | 37.8 (14.7)     | 41.6 (37.8)         |
| Duration of ICU admission prior to enrolment (days)  | 15.2 (7.6)      | 14.2 (9.5)          |
| Indication for ICU admission                        |                 |                     |
| Post general surgical                               | 4 (36.4%)       | 4 (36.4)            |
| Neurological                                        | 2 (18.2)        | 1 (9.1)             |
| Respiratory                                         | 3 (27.3)        | 0                   |
| Cardiovascular                                      | 2 (18.2)        | 1 (9.1)             |
| Post cardiac surgery                                | 0               | 3 (27.3)            |
| Renal failure                                       | 0               | 1 (9.1)             |
| Toxicological                                       | 0               | 1 (9.1)             |
| Testosterone level*                                 |                 |                     |
| Males                                               | 1 (0.74)        | 3 (1.30)            |
| Females                                             |                 | 0.5 (0.30)          |
| Baseline physical scores (at enrolment)             |                 |                     |
| Mid arm circumference (cm)                          |                 |                     |
| Right                                               | 27.6 (5.0)      | 27.2 (6.1)          |
| Left                                                | 27.4 (4.4)      | 27.3 (5.8)          |
|                          | Placebo   | Nandrolone | p   |
|--------------------------|-----------|------------|-----|
| Medical research council (MRC) sum score | 28.2 (14.5) | 40.5 (8.2)* |     |
| Chelsea Critical Care Physical Assessment Tool (CPAx) | 14.8 (7.5) | 24.7 (8.9) |     |
| CPAx ≤18 (at risk)       | 6 (54.5)  | 4 (36.4)   |     |
| ICU mobility scale (IMS) | 2.7 (1.3) | 5.1 (1.9)  |     |
| IMS < 8^                 | 10        | 9          |     |
| Grip strength            |           |            |     |
| Left                     | 2.9 (0.4, 7.3) | 6.5 (2.8, 10.2) | |
| Right                    | 3.4 (0.3, 6.2) | 9.6 (3.2, 12.0) | |

Data are expressed as mean (standard deviation), frequency (prevalence in %), or median (interquartile range (25th-75th percentile)).

^Normal range males 10-35 nmol/L. Females < 2nmol/L.

^ ICU mobility scale of 8 or above = walking with one assist.

Table 2. Treatments received during rehabilitation period

|                          | Placebo | Nandrolone | p   |
|--------------------------|---------|------------|-----|
| Corticosteroid use n(%)  | 3 (27.3)| 1 (11.1)   | 0.590|
| Calorie intake (kJ) mean (SD) | 1857 (465) | 1259 (349) | 0.003|
| Protein intake (g/day) mean (SD) | 85.7 (20.8) | 59.3 (18.9) | 0.005|
| Duration of physiotherapy received (minutes) med (IQR) | 240 (173-500) | 135 (85-240) | 0.067|
| Number of doses received n | 2       | 2          | 0.062|
| 1                        | 2       | 2          | |
| 2                        | 2       | 7          | |
| 3                        | 7       | 2          | |

Table 3. Primary and Secondary Outcomes
| Outcomes                                      | Placebo     | Nandrolone  | P value |
|----------------------------------------------|-------------|-------------|---------|
| **Primary outcomes**                         |             |             |         |
| MRC change*                                  | 17.6 (8.9)  | 9.3 (5.7)   | 0.001   |
| Grip strength change (L)                     | 4.4 (0.8,7.0)| 9.9 (4.9,12.1)| 0.190   |
| Grip strength change (R)                     | 3.0 (2.1, 6.3)| 5.8 (3.6, 8.0)| 0.343   |
| ICU mobility score change*                   | 3 (2.0)     | 3.6 (2.1)   | 0.530   |
| CPAx change                                  | 16.4 (11.1) | 17.2 (7.9)  | 0.865   |
| **Secondary outcomes**                       |             |             |         |
| Length of invasive ventilation, hours        | 377 (189-581)| 168 (164-305)| 0.076   |
| ICU length of stay, days                     | 23 (16–29)  | 14 (12–18)  | 0.047   |
| Hospital length of stay, days                | 36 (28-43)  | 26 (20-37)  | 0.056   |
| ICU readmission rate, n (%)                  | 3 (30%)     | 1 (11.1%)   | 0.582   |
| ICU survival, n (%)                          | 9 (82%)     | 11 (100%)   | 0.476   |
| 90 day survival, n (%)                       | 9 (82%)     | 11 (100%)   | 0.476   |
| Discharge destination                         |             |             | 0.010   |
| Home                                         | 0 (0%)      | 6 (54%)     |         |
| Other (rehab/other hospital)                 | 9 (82%)     | 5 (45%)     |         |
| Death in hospital                            | 2 (18%)     | 0 (0%)      |         |
| Discharge MRC score*                         | 42.7 (13.4) | 49.8 (7.6)  | 0.006   |
| MRC ≥48                                      | 4 (36.4%)   | 6 (54.5%)   | 0.673   |
| Discharge ICU mobility scale score*          | 5.8 (2.2)   | 8.4 (1.7)   | 0.005   |
| IMS ≥8 (walking with one assist)             | 3 (27.3%)   | 6 (54.5%)   | 0.637   |
| Discharge CPAx score*                        | 31.6 (11.1) | 42.8 (6.0)  | 0.011   |
| CPAx > 18                                    | 7 (63.6%)   | 8 (72.7%)   | 0.471   |

Data are expressed as median (interquartile range (25th–75th percentile, values separated by comma), *mean (std deviation) or frequency (prevalence in %).

*Change relates to difference from baseline measurement at enrolment, to last measured score prior to discharge.

Table 4. SF 36 scores at 3 months following enrolment.
|                                      | Placebo (n=7) | Nandrolone (n=9) | p-value |
|--------------------------------------|---------------|------------------|---------|
| Physical functioning                 | 40.7 (28.4)   | 56.6 (32.6)      | 0.32    |
| Role limitations due to physical functioning | 17.9 (27.8)   | 58.3 (50)        | 0.076   |
| Role limitations due to emotional functioning | 42.9 (53.5)   | 74.1 (43.4)      | 0.22    |
| Energy/fatigue                       | 40 (31.8)     | 48.9 (24.8)      | 0.54    |
| Emotional well-being                 | 76 (22.9)     | 80.1 (30.9)      | 0.73    |
| Social functioning                   | 59.1 (31.9)   | 72.3 (31.1)      | 0.42    |
| Pain                                 | 47.4 (27.4)   | 77.6 (31.6)      | 0.065   |
| General health                       | 50 (27.2)     | 51.7 (29.4)      | 0.91    |
| Health change                        | 46.4 (33.6)   | 41.7 (33.1)      | 0.78    |

Values displayed as mean (standard deviation).

**Supplemental table 1. Changes in physical strength and laboratory values over time.**
|                         | Baseline | Day 7     | Day 14    | Day 21    |
|-------------------------|----------|-----------|-----------|-----------|
| **Grip strength (kg/force)** |          |           |           |           |
| (R)                     |          |           |           |           |
| Placebo                 | 3.6 (0.7, 6.5) | 7.4 (4.4, 10.4) | 7.7 (3.7, 10.7) | 7.7 (4.5, 11.0) |
| Nandrolone              | 8.4 (5.5, 11.3) | 10.3 (7.3, 13.2) | 11.9 (8.5, 15.4) | 13.3 (9.9, 16.7) |
| **Grip strength (L)**   |          |           |           |           |
| Placebo                 | 4.1 (0.5, 7.7) | 5.7 (2.0, 9.4) | 7.6 (3.9, 11.3) | 8.3 (4.5, 12.1) |
| Nandrolone              | 8.5 (4.9, 12.1) | 11.5 (7.8, 15.2) | 12.2 (8.0, 16.3) | 16.5 (12.5, 20.7) |
| **Weight (kg)**         |          |           |           |           |
| Placebo                 | 78.1 (63.8, 92.3) | 76.5 (62.2, 90.7) | 72.8 (58.4, 87.2) | *          |
| Nandrolone              | 74.1 (61.3, 86.9) | 71.6 (58.5, 84.6) | 71.2 (57.0, 85.5) |           |
| **Mid-Quad USS (R)**    |          |           |           |           |
| Placebo                 | 1.13 (0.9, 1.4) | 1.06 (0.8, 1.3) | 1.09 (0.8, 1.4) | *          |
| Nandrolone              | 1.32 (1.1, 1.6) | 1.29 (1.0, 1.6) | 1.11 (0.8, 1.5) |           |
| **Mid-Quad USS (L)**    |          |           |           |           |
| Placebo                 | 1.23 (1.0, 1.5) | 0.99 (0.7, 1.2) | 1.12 (0.8, 1.4) | *          |
| Nandrolone              | 1.27 (1.0, 1.5) | 1.24 (1.0, 1.5) | 1.17 (0.9, 1.5) |           |
| **2/3 Quad USS (R)**    |          |           |           |           |
| Placebo                 | 0.95 (0.7, 1.2) | 0.83 (0.6, 1.1) | 0.94 (0.7, 1.2) | *          |
| Nandrolone              | 1.07 (0.8, 1.3) | 1.10 (0.9, 1.3) | 0.84 (0.6, 1.1) |           |
| **2/3 Quad USS (L)**    |          |           |           |           |
| Placebo                 | 1.02 (0.8, 1.2) | 0.83 (0.6, 1.0) | 0.97 (0.7, 1.2) | *          |
| Nandrolone              | 0.99 (0.8, 1.2) | 1.01 (0.8, 1.2) | 1.03 (0.8, 1.3) |           |
| **Biceps (cm) (L)**     |          |           |           |           |
| Placebo                 | 28.8 (25.2, 32.4) | 28.8 (25.2, 32.4) | 26.3 (22.4, 30.3) | *          |
| Nandrolone              | 27.8 (24.7, 30.8) | 26.6 (23.3, 29.8) | 26.5 (22.7, 30.3) |           |
| **Biceps (cm) (R)**     |          |           |           |           |
| Placebo                 | 29.5 (25.9, 33.0) | | | *          |
|                | Placebo  | Nandrolone | Placebo  | Nandrolone | Placebo  | Nandrolone |
|----------------|----------|------------|----------|------------|----------|------------|
| Nandrolone     | 28.1 (25.1, 31.1) | 28.9 (25.4, 32.5) | 26.3 (22.5, 30.1) | 26.2 (23.0, 29.3) | 26.2 (22.6, 29.7) |
| Blood parameters |          |            |          |            |          |            |
| Haemoglobin    | 94.2 (85.9, 102) | 95.3 (86.8, 104) | 95.3 (86.8, 104) | 90.4 (81.7, 99.1) |
| Placebo        | 84.7 (76.5, 93) | 91.2 (82.9, 99.5) | 91.2 (82.9, 99.5) | 95.7 (86.8, 105) |
| Nandrolone     |          |            |          |            |          |            |
| ALT            | 115.4 (82.0, 149) | 55.8 (20.4, 91.3) | 30.1 (-7.9, 68.0) | 39.5 (-1.8, 80.7) |
| Placebo        | 55.9 (22.7, 89.2) | 41.9 (8.5, 75.3) | 34.4 (-3.7, 72.5) | 28.0 (-35.3, 91.1) |
| Nandrolone     |          |            |          |            |          |            |
| Triglycerides  | 2.2 (1.3, 3.2) | 2.2 (1.2, 3.2) | 2.5 (1.5, 3.4) | 2.2 (1.2, 3.2) |
| Placebo        | 2.0 (1.1, 2.9) | 2.3 (1.4, 3.2) | 2.3 (1.3, 3.3) | 1.9 (0.9, 2.9) |
| Nandrolone     |          |            |          |            |          |            |
| LDL            | 2.5 (1.8, 3.3) | 2.5 (1.7, 3.3) | 2.7 (2.0, 3.5) | 2.8 (2.0, 3.6) |
| Placebo        | 1.4 (0.7, 2.1) | 1.8 (1.1, 2.5) | 1.3 (2.0, 3.6) | 1.6 (0.7, 2.4) |
| Nandrolone     |          |            |          |            |          |            |
| Albumin        | 30.8 (27.9, 33.8) | 30.0 (26.9, 33.2) | 31.1 (27.8, 34.4) | 31.8 (27.9, 35.7) |
| Placebo        | 30.1 (27.1, 33.1) | 32.2 (29.1, 35.3) | 30.4 (27.0, 33.9) | 32.8 (27.9, 37.8) |
| Nandrolone     |          |            |          |            |          |            |
| Creatinine     | 80.3 (36.5, 124) | 87.1 (41.7, 132) | 61.4 (14.3, 108) | 52.4 (-2.0, 106.9) |
| Placebo        | 175 (131.2, 218.7) | 166.4 (123, 210) | 139 (91.9, 186) | 102.5 (30.5, 175) |
| Nandrolone     |          |            |          |            |          |            |

ALT – alanine aminotransferase, LDL – low density lipoprotein

# All values are estimated mean, (95% confidence interval).

Ultrasound measurements are in cm.
* Insufficient data points for inclusion in table.